Viatris, formed in November 2020 from the merger of Mylan with Pfizer’s Upjohn division, has established an eye care division following the closure of two acquisitions on...

Viatris, the new US pharma created in the 2020 merger of Mylan and Pfizer’s Upjohn off-patent franchise, is selling its biosimilars portfolio to Biocon Biologics for up...

Pfizer has completed the spin-off of its Upjohn Business and combined it with Mylan to form Viatris, which began trading on Nov. 17. On closure of the deal, Pfizer...